1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Minervax ApS

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2010

Location

Copenhagen Denmark

Primary Industry

Biotechnology

About

Founded in 2010, and based in Copenhagen, Denmark, Minervax ApS operates as a biotechnology company that develops vaccines for the treatment of Group B Streptococcal infections in newborn babies. As of 2024, the company is headed by its CEO Per Fischer. In October 2023, the firm raised EUR 54 million in venture funding co-led by investors EQT Life Sciences and OrbiMed Advisors, with participation from returning investors Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures and LF Invest.
Current Investors
SEED Capital, Heartcore Capital, Novo Seeds

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.minervax.com
Company Stage
Series B
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo